Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование фазы 3 эффективности и безопасности антитромбина, полученного из плазмы человека (Атенатив), у гепарин-резистентных пациентов, которым запланирована кардиохирургическая операция, требующая искусственного кровообращения

23 сентября 2026 г. обновлено: Octapharma

Фаза 3, двойное слепое, плацебо-контролируемое, многоцентровое исследование эффективности и безопасности полученного из плазмы человека антитромбина (Атенатив) у гепарин-резистентных пациентов, которым запланирована кардиохирургическая операция, требующая искусственного кровообращения.

The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)

Обзор исследования

Тип исследования

Интервенционный

Регистрация (Оцененный)

120

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Места учебы

      • Innsbruck, Австрия
        • Рекрутинг
        • University Hospital Innsbruck
      • Vienna, Австрия
        • Рекрутинг
        • Vienna General Hospital AKH, Medical University of Vienna
    • British Columbia
      • New Westminster, British Columbia, Канада, V3L0A4
        • Рекрутинг
        • Royal Columbian Hospital
    • Ontario
      • Kingston, Ontario, Канада, K7L2V7
        • Рекрутинг
        • Kingston Health Sciences Centre
      • Toronto, Ontario, Канада, M5G2C4
        • Еще не набирают
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Канада, H1T1C8
        • Рекрутинг
        • Montreal Heart Institute
      • Kaunas, Литва
        • Прекращено
        • Hospital of Lithuanian university of Health sciences Kauno Klinikos
      • Vilnius, Литва
        • Рекрутинг
        • Vilnius University hospital Santaros Klinikos
      • Bucharest, Румыния
        • Рекрутинг
        • Institute for Cardiovascular Diseases C.C. Iliescu
      • Kamenitz, Сербия
        • Рекрутинг
        • Institute of Cardiovascular Diseases Vojvodina
      • Ljubljana, Словения
        • Рекрутинг
        • University Medical Centre Ljubljana
      • Cambridge, Соединенное Королевство
        • Рекрутинг
        • Royal Papworth Hospital
      • Coventry, Соединенное Королевство
        • Рекрутинг
        • University Hospital Coventry and Warwickshire
      • Middlesbrough, Соединенное Королевство
        • Рекрутинг
        • The James Cook University Hospital
    • California
      • Stanford, California, Соединенные Штаты, 94305-5101
        • Рекрутинг
        • Stanford University School of Medicine
    • Florida
      • Miami, Florida, Соединенные Штаты, 33136
        • Рекрутинг
        • University of Miami
    • Massachusetts
      • Boston, Massachusetts, Соединенные Штаты, 02114
        • Рекрутинг
        • Massachusetts General Hospital
    • North Carolina
      • Durham, North Carolina, Соединенные Штаты, 27710-1000
        • Рекрутинг
        • Duke University Medical Center
      • Winston-Salem, North Carolina, Соединенные Штаты, 27157
        • Рекрутинг
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cleveland, Ohio, Соединенные Штаты, 44195
        • Рекрутинг
        • Cleveland Clinic
      • Columbus, Ohio, Соединенные Штаты, 43214
        • Рекрутинг
        • The Ohio State University
    • Oklahoma
      • Oklahoma City, Oklahoma, Соединенные Штаты, 73104
        • Рекрутинг
        • OU Health University of Oklahoma Medical Center
    • Texas
      • Dallas, Texas, Соединенные Штаты, 75390
        • Рекрутинг
        • University of Texas Southwestern Medical Center
      • Reims, Франция
        • Прекращено
        • CHU de Reims, Hôpital Robert Debré
      • Rennes, Франция
        • Отозван
        • CHU de Rennes
      • Brno, Чехия
        • Рекрутинг
        • Center of Cardiovascular and Transplant Surgery
      • Prague, Чехия
        • Прекращено
        • Institute for Clinical and Experimental Medicine

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 85 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  1. Planned cardiac surgery with CPB
  2. Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
  3. Patients between 18 and 85 years of age, inclusive
  4. Freely given written or electronic informed consent
  5. In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery

Exclusion Criteria:

  1. Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:

    1. vitamin K antagonists (within 3 days)
    2. direct oral anticoagulants (within 2 days)
    3. thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    4. ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    5. glycoprotein IIb/IIIa antagonist (within 24 hours)
  2. Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)

  3. Renal insufficiency, defined as serum creatinine level >2.0 mg/dL

  4. Thrombocytosis, defined as platelet count >400,000 per μL

  5. Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid

  6. History of anaphylactic reaction(s) to blood or blood components

  7. Refusal to receive transfusion of blood or blood-derived products

  8. Current participation in another interventional clinical trial or previous participation in the current trial

  9. Treatment with any IMP within 30 days prior to screening visit

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Тройной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Low-dose Atenativ

Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ.

A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

Экспериментальный: High-dose Atenativ

Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ.

A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

Плацебо Компаратор: Placebo

Patients will receive a saline bolus dose

Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Restoring heparin responsiveness
Временное ограничение: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Amounts of further therapy for restoring heparin responsiveness
Временное ограничение: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
Change in activated clotting time (ACT) values
Временное ограничение: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion

The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo

Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
Change in antithrombin plasma levels
Временное ограничение: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion

The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo

Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
Change in heparin usage
Временное ограничение: From end of IMP infusion to the end of surgery

The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo

From end of IMP infusion to the end of surgery
FP unit use
Временное ограничение: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first

The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
Временное ограничение: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first

The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first)

From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
Transfusion of allogenic blood products
Временное ограничение: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Administration of coagulation factor concentrates
Временное ограничение: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Administration of other haemostatic-relevant therapies
Временное ограничение: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
Postoperative chest tube drainage
Временное ограничение: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first

The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first

From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
Need for reoperation due to bleeding
Временное ограничение: 24 hours after the start of IMP infusion

Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical)

24 hours after the start of IMP infusion
Cell saver volume
Временное ограничение: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

The comparison between cell saver volume until the end of surgery

During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
Adverse events
Временное ограничение: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first

Incidence of adverse events, including all related and non-related, non-serious adverse events

From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
Serious adverse events
Временное ограничение: From the start of IMP infusion until 28 days after IMP administration

Incidence of serious adverse events

From the start of IMP infusion until 28 days after IMP administration
Survival status
Временное ограничение: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration

Number of patients surviving in all three cohorts

At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
Red Blood Cell count
Временное ограничение: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
White Blood Cell count
Временное ограничение: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
Haemoglobin levels
Временное ограничение: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
Haematocrit
Временное ограничение: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
Platelet count
Временное ограничение: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Standard haematological parameter

Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

21 августа 2024 г.

Первичное завершение (Оцененный)

1 марта 2028 г.

Завершение исследования (Оцененный)

1 марта 2028 г.

Даты регистрации исследования

Первый отправленный

17 октября 2023 г.

Впервые представлено, что соответствует критериям контроля качества

17 октября 2023 г.

Первый опубликованный (Действительный)

23 октября 2023 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

28 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

23 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться